550 related articles for article (PubMed ID: 30580380)
21. Interim
Jo JC; Yoon DH; Kim S; Lee K; Kang EH; Park JS; Ryu JS; Huh J; Park CS; Kim JH; Lee SW; Suh C
Ann Hematol; 2017 Sep; 96(9):1509-1515. PubMed ID: 28725988
[No Abstract] [Full Text] [Related]
22. Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma?
Malikova H; Koubska E; Weichet J; Klener J; Rulseh A; Liscak R; Vojtech Z
Cancer Imaging; 2016 Nov; 16(1):40. PubMed ID: 27894359
[TBL] [Abstract][Full Text] [Related]
23. [Positron emission tomography combined with computed tomography in the initial evaluation and response assessment in primary central nervous system lymphoma].
Mercadal S; Cortés-Romera M; Vélez P; Climent F; Gámez C; González-Barca E
Med Clin (Barc); 2015 Jun; 144(11):503-6. PubMed ID: 25433778
[TBL] [Abstract][Full Text] [Related]
24. Primary central nervous system lymphoma and glioblastoma differentiation based on conventional magnetic resonance imaging by high-throughput SIFT features.
Chen Y; Li Z; Wu G; Yu J; Wang Y; Lv X; Ju X; Chen Z
Int J Neurosci; 2018 Jul; 128(7):608-618. PubMed ID: 29183170
[TBL] [Abstract][Full Text] [Related]
25. Neuroimaging of primary central nervous system lymphoma in immunocompetent patients: comparison of recent and previous findings.
Adachi K; Yamaguchi F; Node Y; Kobayashi S; Takagi R; Teramoto A
J Nippon Med Sch; 2013; 80(3):174-83. PubMed ID: 23832401
[TBL] [Abstract][Full Text] [Related]
26. A case report of primary central nervous system lymphoma.
Zeng X; Lu X; Li X; Peng L; Chen L
J Int Med Res; 2020 Jul; 48(7):300060520937839. PubMed ID: 32660288
[TBL] [Abstract][Full Text] [Related]
27. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up.
Palmedo H; Urbach H; Bender H; Schlegel U; Schmidt-Wolf IG; Matthies A; Linnebank M; Joe A; Bucerius J; Biersack HJ; Pels H
Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):164-8. PubMed ID: 16220304
[TBL] [Abstract][Full Text] [Related]
28. What is the Best Preoperative Quantitative Indicator to Differentiate Primary Central Nervous System Lymphoma from Glioblastoma?
Inoue A; Matsumoto S; Ohnishi T; Miyazaki Y; Kinnami S; Kanno K; Honda T; Kurata M; Taniwaki M; Kusakabe K; Suehiro S; Yamashita D; Shigekawa S; Watanabe H; Kitazawa R; Kunieda T
World Neurosurg; 2023 Apr; 172():e517-e523. PubMed ID: 36690204
[TBL] [Abstract][Full Text] [Related]
29. Enhanced MRI and 18F-FDG PET/CT Findings of Primary Central Nervous System Lymphoma Mimicking Encephalitis.
Ge J; Zuo C; Guan Y; Zhao G
Clin Nucl Med; 2016 Oct; 41(10):e436-8. PubMed ID: 27355853
[TBL] [Abstract][Full Text] [Related]
30. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma.
Karantanis D; O'Neill BP; Subramaniam RM; Peller PJ; Witte RJ; Mullan BP; Wiseman GA
Clin Nucl Med; 2007 Apr; 32(4):271-4. PubMed ID: 17413571
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography.
Kim HO; Kim JS; Kim SO; Chae SY; Oh SJ; Seo M; Lee SH; Oh JS; Ryu JS; Huh JR; Kim JH
Medicine (Baltimore); 2020 May; 99(20):e20140. PubMed ID: 32443328
[TBL] [Abstract][Full Text] [Related]
32. 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients.
Karantanis D; O'eill BP; Subramaniam RM; Witte RJ; Mullan BP; Nathan MA; Lowe VJ; Peller PJ; Wiseman GA
Nucl Med Commun; 2007 Nov; 28(11):834-41. PubMed ID: 17901765
[TBL] [Abstract][Full Text] [Related]
33. Imaging in primary central nervous system lymphoma.
Lolli V; Tampieri D; Melançon D; Delpilar Cortes M
Neuroradiol J; 2010 Dec; 23(6):680-9. PubMed ID: 24148721
[TBL] [Abstract][Full Text] [Related]
34. Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.
Chen T; Liu Y; Wang Y; Chang Q; Wu J; Wang Z; Geng D; Yu JT; Li Y; Li XQ; Chen H; Zhuang D; Li J; Wang B; Jiang T; Lyu L; Song Y; Qiu X; Li W; Lin S; Zhang X; Lu D; Lei J; Chen Y; Mao Y
J Hematol Oncol; 2022 Sep; 15(1):136. PubMed ID: 36176002
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Significance of Interim 11C-Methionine PET/CT in Primary Central Nervous System Lymphoma.
Ahn SY; Kwon SY; Jung SH; Ahn JS; Yoo SW; Min JJ; Bom HS; Ki SY; Kim HJ; Lee JJ; Song SY; Yang DH
Clin Nucl Med; 2018 Aug; 43(8):e259-e264. PubMed ID: 29877882
[TBL] [Abstract][Full Text] [Related]
36. Central nervous system lymphoma: a morphological MRI study.
Koubska E; Weichet J; Malikova H
Neuro Endocrinol Lett; 2016 Sep; 37(4):318-324. PubMed ID: 27857050
[TBL] [Abstract][Full Text] [Related]
37. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
Albano D; Patti C; Lagalla R; Midiri M; Galia M
J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
[TBL] [Abstract][Full Text] [Related]
38. Differentiating Glioblastoma from Primary Central Nervous System Lymphoma: The Value of Shaping and Nonenhancing Peritumoral Hyperintense Gyral Lesion on FLAIR Imaging.
Wang P; Shi YH; Li JY; Zhang CZ
World Neurosurg; 2021 May; 149():e696-e704. PubMed ID: 33548537
[TBL] [Abstract][Full Text] [Related]
39. Neuroinflammation preceding primary central nervous system lymphoma (PCNSL) - Case reports and literature review.
Norrington M; Rathi N; Jenkinson MD; Mills SJ
J Clin Neurosci; 2021 Jul; 89():381-388. PubMed ID: 34083111
[TBL] [Abstract][Full Text] [Related]
40. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.
Raizer JJ; Koutcher JA; Abrey LE; Panageas KS; DeAngelis LM; Lis E; Xu S; Zakian KL
J Neurooncol; 2005 Jan; 71(2):173-80. PubMed ID: 15690135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
